Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Siliprandi N, Di Lisa F, et al
This was published in the New England Journal of Medicine: About 16.6 % average weight loss in participants who remained on treatment for 64 weeks
Recommendations from the study include that more extensive multicenter studies or prospective clinical trials are needed to confirm findings and explore causality
Who its for May be a fit if you Want the FDA-approved brand-name tirzepatide specifically Want a dual-pathway option for appetite control Prefer a once-weekly injection pen Want licensed provider oversight and ongoing support Not appropriate if you Have a personal or family history of medullary thyroid carcinoma or MEN 2 Are pregnant, trying to conceive, or breastfeeding Have a history of pancreatitis or certain GI conditions (discuss with your provider) Are advised against GLP-1 care by your provider Eligibility is always determined by a licensed provider after reviewing your intake
US$ 26.60
US$ 21.87
US$ 26.56
US$ 25.56
US$ 29.38
US$ 25.62
US$ 27.80
US$ 27.61
US$ 21.12
US$ 21.56
US$ 22.04
